Vaxart, Inc. (VXRT) said it has begun recruiting subjects for phase II COVID-19 oral tablet vaccine clinical trial. The company plans to begin dosing the first of 96 U.S. subjects, split evenly between COVID-19 naïve and mRNA vaccinated subjects, later this month.
The company's phase II COVID-19 program will also include countries outside of the U.S., starting with a trial in India that is anticipated to begin later in the current year.
Vaxart said new trials will generate key data that will allow it to compare the S-only and S+N vaccine candidates and help decide on the best development path forward for COVID-19 vaccine program.
For comments and feedback contact: editorial@rttnews.com
Business News